EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2.
These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting the results of fluorine-18 fluoro-2-deoxyglucose ([(18)F]FDG) PET imaging of the brain. The aim is to help achieve a high standard of FDG imaging, which will increase the diagnostic impact of this technique in neurological and psychiatric practice. The present document replaces a former version of the guidelines that were published in 2002 [1] and includes an update in the light of advances in PET technology, the introduction of hybrid PET/CT systems and the broadening clinical indications for FDG brain imaging. These guidelines are intended to present information specifically adapted for European practice. The information provided should be taken in the context of local conditions and regulations.
Varrone
Andrea
A
Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Karolinska Hospital R5:02, 17176 Stockholm, Sweden.
Asenbaum
Susanne
S
Vander Borght
Thierry
T
Booij
Jan
J
Nobili
Flavio
F
Någren
Kjell
K
Darcourt
Jacques
J
Kapucu
Ozlem L
OL
Tatsch
Klaus
K
Bartenstein
Peter
P
Van Laere
Koen
K
D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging*; D002648:Child; D000075202:Contraindications; D005060:Europe; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000009:adverse effects; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D010346:Patient Care Management; D049268:Positron-Emission Tomography / Q000009:adverse effects / Q000379:methods*; D011247:Pregnancy; D058028:Research Report; D012952:Societies
D019788:Fluorodeoxyglucose F18